About Serine/threonine-protein phosphatase PP1-gamma catalytic subunit
Serine/threonine-protein phosphatase PP1-gamma catalytic subunit (PPP1CC) is a protein
from Homo sapiens identified by UniProt accession
P36873, 323 residues long.
MolForge cross-references it against 0 known binders and
174 disease associations.
Target properties
| Protein name | Serine/threonine-protein phosphatase PP1-gamma catalytic subunit |
| UniProt accession | P36873 |
| Gene | PPP1CC |
| Organism | Homo sapiens |
| Length | 323 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (174)
Diseases linked to this target (Open Targets).
- Noonan syndrome · score 0.46
- esophageal carcinoma · score 0.37
- neurodegenerative disease · score 0.26
- eosinophil count · score 0.19
- esophageal cancer · score 0.10
- azoospermia · score 0.10
- glioblastoma multiforme · score 0.10
- partial chromosome Y deletion · score 0.09
- male infertility with teratozoospermia due to single gene mutation · score 0.09
- spermatogenic failure 25 · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P36873-F1 | alphafold | PREDICTED | 92.67 | — |
Amino-acid sequence (323 residues)
MADLDKLNID SIIQRLLEVR GSKPGKNVQL QENEIRGLCL KSREIFLSQP ILLELEAPLK ICGDIHGQYY DLLRLFEYGG FPPESNYLFL GDYVDRGKQS LETICLLLAY KIKYPENFFL LRGNHECASI NRIYGFYDEC KRRYNIKLWK TFTDCFNCLP IAAIVDEKIF CCHGGLSPDL QSMEQIRRIM RPTDVPDQGL LCDLLWSDPD KDVLGWGEND RGVSFTFGAE VVAKFLHKHD LDLICRAHQV VEDGYEFFAK RQLVTLFSAP NYCGEFDNAG AMMSVDETLM CSFQILKPAE KKKPNATRPV TPPRGMITKQ AKK
Explore Serine/threonine-protein phosphatase PP1-gamma catalytic subunit with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets